Sleep Drugs Rouse Big Pharma

With 25 million Americans suffering from chronic insomnia, new treatments in the pipeline could find a huge market

New York may be the "City That Never Sleeps," but the rest of the U.S. seems to be getting less shut-eye as well. Pharma and biotech companies are targeting sleeping disorders, with more than a dozen insomnia compounds in phase II and phase III clinical trials.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.